Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Exciting updates in MF: novel targets and agents

Lucia Masarova • 26 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Imetelstat Navitoclax Parsaclisib Ruxolitinib

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some exciting updates and novel agents to look out for in myelofibrosis (MF), including navitoclax, parsaclisib, and imetelstat. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Lucia Masarova

Promising combination strategies being explored in myelofibrosis 3:27
Promising combination strategies being explored in myelofibrosis
Lucia Masarova • 22 Aug 2025
The most promising emerging therapies and developments in PV and ET 1:56
The most promising emerging therapies and developments in PV and ET
Lucia Masarova • 22 Aug 2025
The rationale for investigating T-regulatory cell therapy in myelofibrosis 2:24
The rationale for investigating T-regulatory cell therapy in myelofibrosis
Lucia Masarova • 22 Aug 2025
An update on BET inhibition for the treatment of myelofibrosis 2:34
An update on BET inhibition for the treatment of myelofibrosis
Lucia Masarova • 22 Aug 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals